Back to search

Article

Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 As Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study

2021-10-26

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to efficiently treat desmoid tumor. However, molecular mechanism of why imatinib works remains poorly understood. Here, we describe the potential roles of <italic>NOTCH2</italic> and <ital...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d1025855-aba4-5860-9055-3ec323a75538
DOI
10.21203/rs.3.rs-993539/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 As Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial StudyDOI 10.21203/rs.3.rs-993539/v1
Select a neighboring publication to make it the new centre.